BeiGene Ltd. (BGNE) Director Bros. Advisors Lp Baker Purchases 1,760,495 Shares of Stock
BeiGene Ltd. (NASDAQ:BGNE) Director Bros. Advisors Lp Baker bought 1,760,495 shares of the firm’s stock in a transaction that occurred on Friday, November 18th. The shares were acquired at an average cost of $32.00 per share, for a total transaction of $56,335,840.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of BeiGene Ltd. (NASDAQ:BGNE) opened at 31.51 on Tuesday. BeiGene Ltd. has a 52-week low of $22.51 and a 52-week high of $37.89. The stock’s 50 day moving average price is $32.77 and its 200-day moving average price is $30.04. The company’s market capitalization is $1.04 billion.
BeiGene (NASDAQ:BGNE) last posted its earnings results on Thursday, November 10th. The company reported ($1.08) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.78) by $0.30. On average, equities analysts expect that BeiGene Ltd. will post ($3.96) earnings per share for the current year.
BGNE has been the topic of a number of recent analyst reports. Zacks Investment Research lowered BeiGene from a “hold” rating to a “sell” rating in a report on Monday, August 15th. Cowen and Company reaffirmed a “buy” rating on shares of BeiGene in a report on Friday, October 7th. Finally, Maxim Group began coverage on BeiGene in a report on Wednesday, September 21st. They issued a “buy” rating and a $41.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $40.00.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. raised its position in BeiGene by 3,410.1% in the second quarter. BlackRock Inc. now owns 3,826 shares of the company’s stock worth $114,000 after buying an additional 3,717 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in shares of BeiGene by 67.9% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 6,404 shares of the company’s stock worth $191,000 after buying an additional 2,589 shares during the period. Bank of Montreal Can acquired a new stake in shares of BeiGene during the second quarter worth approximately $191,000. Credit Suisse AG raised its stake in shares of BeiGene by 9.1% in the third quarter. Credit Suisse AG now owns 12,000 shares of the company’s stock worth $370,000 after buying an additional 1,000 shares during the period. Finally, Susquehanna International Group LLP acquired a new stake in shares of BeiGene during the third quarter worth approximately $455,000. Institutional investors own 25.83% of the company’s stock.
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.
Receive News & Stock Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related stocks with our FREE daily email newsletter.